Want to see LBRX full AI Analyst Report?

LB Pharmaceuticals, Inc. (LBRX) Price & Analysis

43 Followers

LBRX Stock Chart & Stats

$30.52

Market closed

$30.52

Day’s Range― - ―

52-Week Range$13.36 - $35.35

Previous CloseN/A

VolumeN/A

Average Volume (3M)239.05K

Market Cap

$967.55M

Enterprise Value$544.53M

Total Cash (Recent Filing)$365.64M

Total Debt (Recent Filing)$3.47M

Price to Earnings (P/E)―

Beta1.24

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding28,676,653

10 Day Avg. Volume318,803

30 Day Avg. Volume239,047

Financial Highlights & Ratios

PEG Ratio0.24

Price to Book (P/B)1.87

Price to Sales (P/S)0.00

P/FCF Ratio-15.97

Enterprise Value/Market Cap0.56

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-6.64K

Enterprise Value/Ebitda-13.94

Forecast

1Y Price Target

$47.67

Price Target Upside56.18% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering6

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Strengthened Balance SheetThe material 2025 equity turnaround and minimal debt materially reduce near-term solvency risk and extend financial runway. This durable improvement enhances the company’s ability to fund clinical programs, pursue partnerships, and negotiate non-dilutive financing, supporting program continuity.

Governance And Oversight BolsteredBoard continuity and an independent auditor strengthen governance, reporting quality, and strategic oversight. Better corporate governance is a lasting positive for execution, improving investor and partner confidence and reducing operational and compliance risk over multiple reporting cycles.

Improving Cash Burn And Loss TrajectoryThe marked reduction in operating cash outflows and narrower net loss reflect operational progress and cost control. This trend, if maintained, lengthens runway and lowers immediate refinancing frequency, giving management more time to advance trials or secure strategic partnerships.

Bears Say

No Commercial RevenueAs a clinical-stage biotech with no product sales, the firm lacks self-sustaining cash inflows. This structural absence of revenue forces reliance on equity/debt raises or partnerships to fund R&D, increasing dilution risk and making long-term planning contingent on external capital markets.

Consistent Negative Cash GenerationPersistent negative operating and free cash flows demonstrate a structural funding gap. Continued cash burn means recurring external financing will be required to progress clinical programs, limiting strategic flexibility and exposing the company to financing availability and cost over the medium term.

Prior Balance-sheet StressHistorical negative equity signals past solvency challenges and likely frequent capital raises. Even after recovery, legacy stress can leave lasting effects—tighter counterparty terms, reputational financing costs, and investor wariness—that constrain options and increase the premium on future capital.

LB Pharmaceuticals, Inc. News

LB Pharmaceuticals initiated with an Outperform at Wolfe Research

Wolfe Research analyst Rudy Li initiated coverage of LB Pharmaceuticals (LBRX) with an Outperform rating and $45 price...

5d ago

LBRX

Clear Street says Neumora failed trial does not impact LB Pharmaceuticals LB-102

Clear Street analyst Kaveri Pohlman keeps a Buy rating and a $45 price target on LB Pharmaceuticals (LBRX)....

26d ago

LBRX

NMRA

LB Pharmaceuticals Stockholders Approve Directors and Auditor

LB Pharmaceuticals, Inc. ( ($LBRX) ) has shared an announcement. LB Pharmaceuticals, Inc. reported the results of its...

1M ago

LBRX

Eight new option listings and one option delisting on May 28th

New option listings for May 28th include Cantor Equity Partners II Inc (CEPT), DESTINY TECH100 INC (DXYZ), LB...

1M ago

CEPT

DXYZ

LB Pharmaceuticals initiated with a Buy at Clear Street

Clear Street analyst Kaveri Pohlman initiated coverage of LB Pharmaceuticals (LBRX) with a Buy rating and $45 price...

2M ago

LBRX

LB Pharmaceuticals: Buy Rating Reiterated, $45 Price Target Maintained on LB-102 Late-Stage Pipeline and Multi-Billion-Dollar Sales Potential

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on LB Pharmaceuticals, Inc. today and set a price...

2M ago

LBRX

LB Pharmaceuticals price target raised to $37 from $31 at Roth Capital

Roth Capital raised the firm’s price target on LB Pharmaceuticals (LBRX) to $37 from $31 and keeps a...

2M ago

LBRX

LB Pharmaceuticals reports Q1 EPS (67c), consensus (67c)

“With multiple clinical trials ongoing, our focus is on execution to support several clinical readouts over the next...

2M ago

LBRX

LB Pharmaceuticals initiated with a Buy at H.C. Wainwright

H.C. Wainwright initiated coverage of LB Pharmaceuticals (LBRX) with a Buy rating and $45 price target The company...

3M ago

LBRX

LB-102 Bipolar Depression Trial Moves Forward: What LBRX Investors Should Know

LB Pharmaceuticals, Inc. ($LBRX) announced an update on their ongoing clinical study. This Phase II clinical study, titled...

3M ago

LBRX

Craig-Hallum bullish on LB Pharmaceuticals, initiates with a Buy

As previously reported, Craig-Hallum initiated coverage of LB Pharmaceuticals (LBRX) with a Buy rating and $36 price target...

3M ago

LBRX

LB Pharmaceuticals initiated with a Buy at Craig-Hallum

Craig-Hallum initiated coverage of LB Pharmaceuticals (LBRX) with a Buy rating and $36 price target Published first on...

3M ago

LBRX

LB Pharmaceuticals files to sell 4.78M shares of common stock for holders

16:06 EDT LB Pharmaceuticals (LBRX) files to sell 4.78M shares of common stock for holders Published first on...

3M ago

LBRX

LB Pharmaceuticals Announces Director Zachary Prensky’s Planned Retirement

LB Pharmaceuticals, Inc. ( ($LBRX) ) just unveiled an update. On March 13, 2026, LB Pharmaceuticals, Inc. announced...

4M ago

LBRX

LBRX FAQ

What was LB Pharmaceuticals, Inc.’s price range in the past 12 months?

LB Pharmaceuticals, Inc. lowest stock price was $13.36 and its highest was $35.34 in the past 12 months.

What is LB Pharmaceuticals, Inc.’s market cap?

LB Pharmaceuticals, Inc.’s market cap is $967.55M.

When is LB Pharmaceuticals, Inc.’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were LB Pharmaceuticals, Inc.’s earnings last quarter?

Currently, no data Available

Is LB Pharmaceuticals, Inc. overvalued?

According to Wall Street analysts LB Pharmaceuticals, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does LB Pharmaceuticals, Inc. pay dividends?

LB Pharmaceuticals, Inc. does not currently pay dividends.

What is LB Pharmaceuticals, Inc.’s EPS estimate?

LB Pharmaceuticals, Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does LB Pharmaceuticals, Inc. have?

LB Pharmaceuticals, Inc. has 28,676,653 shares outstanding.

What happened to LB Pharmaceuticals, Inc.’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of LB Pharmaceuticals, Inc.?

Currently, no hedge funds are holding shares in LBRX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

LB Pharmaceuticals, Inc. Stock Smart Score

Neutral

Company Description

LB Pharmaceuticals, Inc.

This biopharmaceutical firm is currently in the clinical development stage, concentrating on the creation of innovative treatments for neuropsychiatric disorders such as schizophrenia and bipolar depression. Central to their pipeline is LB-102, their primary investigational drug, which is a methylated variant of amisulpride.

LB Pharmaceuticals, Inc. (LBRX) Earnings & Revenues

Historic Earnings Reports

LBRX Stock 12 Month Forecast

Average Price Target

$47.67

▲(56.18% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"14":"$14","79":"$79","30.25":"$30.3","46.5":"$46.5","62.75":"$62.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":78,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$78.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":47.666666666666664,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$47.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":36,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$36.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[14,30.25,46.5,62.75,79],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,31.89,35.43692307692308,38.98384615384615,42.53076923076923,46.07769230769231,49.62461538461538,53.17153846153846,56.71846153846154,60.26538461538462,63.81230769230769,67.35923076923078,70.90615384615384,74.45307692307692,{"y":78,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,31.89,33.103589743589744,34.31717948717949,35.53076923076923,36.744358974358974,37.95794871794872,39.17153846153846,40.385128205128204,41.59871794871795,42.81230769230769,44.025897435897434,45.23948717948718,46.45307692307692,{"y":47.666666666666664,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,31.89,32.206153846153846,32.52230769230769,32.83846153846154,33.15461538461538,33.47076923076923,33.786923076923074,34.10307692307693,34.41923076923077,34.73538461538462,35.05153846153846,35.36769230769231,35.683846153846154,{"y":36,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":16.8,"date":1751328000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":16.8,"date":1754006400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":16.8,"date":1756684800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":15.76,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.13,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.43,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.26,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.91,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.78,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.81,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.43,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.03,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.89,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >